Full-Time
Business Development Associate
Confirmed live in the last 24 hours
Asimov
51-200 employees
Synthetic biology solutions for biopharmaceuticals
Mid
Remote in UK
- At least 3 years’ experience in a business development or sales role, ideally within the B2B biopharmaceutical tools and/or services sector.
- A deep understanding of the biotherapeutics manufacturing landscape.
- Ability to rapidly build rapport and effectively communicate the benefits of partnering with Asimov.
- Proven track record of growing long-term relationships with clients.
- Knowledge of cell line development and upstream process development for biologics and/or viral vectors.
- A Master's degree in a biologics-based discipline is preferred. Alternatively, a Bachelor's degree in Life Sciences coupled with relevant experience will be considered.
- Proactively source and secure business opportunities with biopharma companies ranging from virtual organisations to big pharma in order to drive significant revenue growth.
- Play a central role in building and nurturing relationships with clients, focusing on customer centricity.
- Effectively convey the technical and commercial benefits of our offerings to potential clients.
- Work closely with the broader Commercial Team to develop deal structures that maximise value for all parties involved.
- Represent Asimov at industry conferences, network with potential partners, and grow awareness of our technologies and services.
Asimov operates in the synthetic biology field, providing a combination of engineered cells, genes, and software to assist in advanced genetic design. Their main products include cloud-based software that helps clients in the biopharmaceutical industry design, simulate, and optimize genetic systems, along with engineered GMP host cells for therapeutic uses. Asimov distinguishes itself from competitors by offering a guarantee on their high titer cell lines for monoclonal antibodies, promising '4 g/L or it's free,' which reduces risk for their clients. The company's goal is to enable biopharma companies to enhance their production of protein therapeutics and scalable viral vectors, ensuring high quality and performance through their specialized teams in synthetic biology and process development.
Company Stage
Series B
Total Funding
$199.1M
Headquarters
Boston, Massachusetts
Founded
2017
6 month growth
↑ 4%1 year growth
↑ 12%2 year growth
↑ 69%
Simplify's Take
What believers are saying
- The launch of the LV Edge Producer System promises scalable, reproducible, and low-cost production of lentivirus, potentially unlocking larger therapeutic applications.
- The establishment of Asimov Labs with The Foundry team enhances Asimov's R&D capabilities, driving forward advanced genetic design and engineering.
- Asimov's innovative approach to synthetic biology and biocomputing could lead to significant breakthroughs in therapeutic development and manufacturing.
What critics are saying
- The complexity of integrating The Foundry's team and infrastructure into Asimov could pose operational challenges.
- The reliance on advanced genetic and computational tools may require substantial ongoing investment in R&D, impacting financial stability.
What makes Asimov unique
- Asimov's LV Edge System offers a unique fully stable cell line development service, eliminating GMP plasmid costs and reducing process complexity, unlike traditional multi-plasmid transfection methods.
- The integration of The Foundry's advanced genetic design capabilities from MIT and the Broad Institute positions Asimov at the forefront of genetic engineering innovation.
- Asimov's focus on combining cellular, genetic, and computational tools to enable next-generation therapeutics sets it apart from competitors who may specialize in only one of these areas.
Help us improve and share your feedback! Did you find this helpful?